Cerus Corporation
CERS
Rank in Stocks
#13059
Cerus Corporation operates as a biotechnology firm dedicated to advancing and... Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Share Price
$2.07
Last synced: 2026-11-09
Market Cap
$418.04M
Change (1 day)
2.48%
Change (1 year)
25.45%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cerus Corporation (CERS)
Category
Healthcare
EPS for Cerus Corporation (CERS)
EPS as of September 2026 TTM: $-0.04
According to Cerus Corporation's latest financial reports, its current EPS (TTM) is $-0.04. At the end of 2025 the company had an EPS of $-0.08, an increase over its 2024 EPS of $-0.11.
EPS history for Cerus Corporation from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.04 | -51.50% |
| 2025 | $-0.08 | -25.45% |
| 2024 | $-0.11 | -47.62% |
| 2023 | $-0.21 | -12.50% |
| 2022 | $-0.24 | -25.00% |
| 2021 | $-0.32 | -13.51% |
| 2020 | $-0.37 | -27.45% |
| 2019 | $-0.51 | 15.91% |
| 2018 | $-0.44 | -21.43% |
| 2017 | $-0.56 | -9.68% |
| 2016 | $-0.62 | 6.90% |
| 2015 | $-0.58 | 11.54% |
| 2014 | $-0.52 | -18.75% |
| 2013 | $-0.64 | 120.69% |
| 2012 | $-0.29 | -17.14% |
| 2011 | $-0.35 | -16.67% |
| 2010 | $-0.42 | -39.13% |
| 2009 | $-0.69 | -23.33% |
| 2008 | $-0.90 | -36.62% |
| 2007 | $-1.42 | 688.89% |
| 2006 | $-0.18 | -131.03% |
| 2005 | $0.58 | -141.13% |
| 2004 | $-1.41 | -53.16% |
| 2003 | $-3.01 | -16.62% |
| 2002 | $-3.61 | 10.40% |
| 2001 | $-3.27 | 18.91% |
| 2000 | $-2.75 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.70 | -7,058.76% |
US
|
|
| $4.09 | -10,641.24% |
IE
|
|
| $9.45 | -24,455.67% |
US
|
|
| $2.37 | -6,208.25% |
US
|
|
| $1.77 | -4,661.86% |
US
|
Questions about Cerus Corporation's earnings per share (EPS)
What is Cerus Corporation's earnings per share (EPS)?
Cerus Corporation's earnings per share (EPS) over the last twelve months is $-0.04, as of Sep 2026.
What was Cerus Corporation's earnings per share (EPS) in 2025?
In 2025, Cerus Corporation's earnings per share (EPS) was $-0.08, compared with $-0.11 in 2024.
How has Cerus Corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cerus Corporation's earnings per share (EPS) was highest in 2025 ($-0.08) and lowest in 2020 ($-0.37).
How does Cerus Corporation's earnings per share (EPS) compare with similar companies?
Cerus Corporation's earnings per share (EPS) ($-0.04) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.